Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin

Journal of Medicinal Chemistry

Volumn 40, Issue 8, 1997, Pages 1276-1286

  Taatjes, Dylan J ^a   Gaudiano, Giorgio ^a,b   Resing, Katheryn ^a   Koch, Tad H ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DITHIOTHREITOL; DNA; DOXORUBICIN; FORMALDEHYDE; HYDROGEN PEROXIDE; SPERMINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; COVALENT BOND; CRYSTAL STRUCTURE; DNA ALKYLATION; INTERCALATION COMPLEX; OXIDATION REDUCTION REACTION; REACTION ANALYSIS;

EID: 0030991136     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960835d     Document Type: Article

References (41)

1. Young, R. C.; Ozols, R. F.; Myers, C. E. Medical Progress: The anthracycline antineoplastic drugs. New Engl. J. Med. 1981, 305, 139-153.
2. Guaglianone, P.; Chan, K.; DelaFlor-Weiss, E.; Hanisch, R.; Jeffers, S.; Sharma, D.; Muggia, F. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest. New Drugs 1994, 12, 103-110.
3. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58, 351-375.
4. Pommier, Y. DNA topoisomerases and their inhibition by anthracyclines. In Anthracycline Antibiotics: New Analogues, Methods of Delivery, and Mechanisms of Action; Priebe, W., Ed.; ACS Symposium Series 574; American Chemical Society: Washington, DC, 1995; pp 183-203.
5. Lown, W. J.; Chen, J. A.; Plambeck, J. A.; Acton, E. M. Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects. Biochem. Pharmacol. 1982, 31, 575-581.
6. Doroshow, J. H. Role of reactive-oxygen metabolism in cardiac toxicity of anthracycline antibiotics. In Anthracycline Antibiotics: New Analogues, Methods of Delivery, and Mechanisms of Action; Priebe, W., Ed.; ACS Symposium Series 574, American Chemical Society: Washington, DC, 1995; pp 259-267.
7. Gaudiano, G.; Koch, T. H. Redox chemistry of anthracycline antitumor drugs and use of captodative radicals as tools for its elucidation and control. Chem. Res. Toxicol. 1991, 4, 2-16.
8. Egholm, M.; Koch, T. H. Coupling of the anthracycline antitumor drug menogaril to 2′-deoxyguanosine through reductive activation. J. Am. Chem. Soc. 1989, 111, 8291-8293.
9. Cullinane, C.; van Rosmalen, A.; Phillips, D. R. Does adriamycin induce interstrand cross-links in DNA? Biochemistry 1994, 33, 4632-4638.
10. Cutts, S. M.; Parsons, P. G.; Sturm, R. A.; Phillips, D. R. Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J. Biol. Chem. 1996, 271, 5422-5429.
11. Cutts, S. M.; Phillips, D. R. Use of oligonuclcotides to define the site of interstrand cross-links induced by Adriamycin. Nucleic Acids Res. 1995, 23, 2450-2456.
12. van Rosmalen, A.; Cullinane, C.; Cutts, S. M.; Phillips, D. R. Stability of adriamycin-induced DNA adducts and interstrand crosslinks. Nucleic Acids Res. 1995, 23, 42-50.
13. Taatjes, D. J.; Gaudiano, G.; Resing, K.; Koch, T. H. Alkylation of DNA by the Anthracycline, Antitumor Drugs Adriamycin and Daunomycin. J. Med. Chem. 1996, 39, 4135-4138.
14. Tong, G.; Lee, W. W.; Black, D. R.; Henry, D. W. Adriamycin Analogs. Periodate Oxidation of Adriamycin. J. Med. Chem. 1976, 19, 395-398.
15. Tong, G.; Lee, W. W.; Black, D. R.; Garnier-Sullerot, A.; Amirand, C.; Ballini, J.-C.; Chinsky, L.; Duquesne, M.; Jolles, B.; Sureau, F.; Turpin, P. Y.; Vigny, P. Interaction of Iron-Anthracycline Complexes with Living Cells: a Microspectrofluorometric Study. Biochem. Biophys. Acta 1993, 1177, 236-244.
16. Nash, T. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem. J. 1953, 55, 416-421.
17. Wang, A. H. J.; Gao, Y. G.; Liaw, Y. C.; Li, Y. k. Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray driffraction studies. Biochemistry 1991, 30, 3812-3815.
18. Gao, Y. G.; Liaw, Y. C.; Li, Y. k.; van der Marel, G.; van Boom, J. H.; Wang, A. H. J. Facile formation of a crosslinked adduct between DNA and the daunorubicin derivative MAR70 mediated by formaldehyde: molecular structure of the MAR70-d(CGT-nACG) covalent adduct. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 4845-4849.
19. Zhang, H.; Gao, Y. G.; van der Marel, G. A.; van Boom, J. H.; Wang, A. H. Simultaneous incorporations of two anticancer drugs into DNA. The structures of formaldehyde-cross-linked adducts of daunorubicin-d(CG(araC)GCG) and doxorubicin-d(CA(araC)GTG) complexes at high resolution. J. Biol. Chem. 1993, 268, 10095-10101.
20. Shiraishi, H.; Kataoka, M.; Morta, Y.; Umemoto, J. Interaction of hydroxyl radicals with tris(hydroxymethyl)aminomethane and Good's buffers containing hydroxylmethyl or hydroxylethyl residues produce formaldehyde. Free Rad. Res. Commun. 1993, 19, 315.
21. Cullinane, C.; Cutts, S. M.; van Rosmalen, A.; Phillips, D. R. Formation of adriamycin-DNA adducts in vitro. Nucleic Acids Res. 1994, 22, 2296-2303.
22. Arcamone, F. Doxorubicin Anticancer Antibiotics; Academic Press: New York, 1981; pp 246-254.
23. Skladanowski, A.; Konopa, J. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem. Pharmacol. 1994, 47, 2279-2287.
24. Skladanowski, A.; Konopa, J. Interstrand DNA crosslinking induced by anthracyclines in tumour cells. Biochem. Pharmacol. 1994, 47, 2269-2278.
25. Myers, C. E.; Gianni, L.; Simone, C. B.; Klecker, R.; Greene, R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 1982, 21, 1707-1712.
26. Myers, C.; Gianni, L.; Zweier, J.; Muindi, J.; Sinha, B. K.; Eliot, H. Role of iron in adriamycin biochemistry. Fed. Proc. 1986, 45, 2792-2797.
27. Leng, F.; Savkur, R.; Fokt, I.; Przewloka, T.; Priebe, W.; Chaires, J. B. Base specific and regiospecific chemical cross-linking of Daunorubicin to DNA. J. Am. Chem. Soc. 1996, 118, 4731-4738.
28. Thorndike, J.; Beck, W. S. Production of formaldehyde from N5-methyltetrahydrofolate by normal and leukemic leukocytes. Cancer Res. 1977, 37, 1125-1132.
29. Ebeler, S. E.; Zulim, R. A.; Hinrichs, S. H.; Clifford, A. J.; Shibamoto, T. Tumor-bearing transgenic mice and cancer patients have elevated levels of expired formaldehyde. Faseb J. 1993, 7, A716.
30. Bagchi, D.; Bagchi, M.; Hassoun, E. A.; Kelly, J.; Stohs, S. J. Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology 1995, 95, 1-9.
31. Bucciarelli, E. Mammary tumor induction in male and female Sprague-Dawley rats by Adriamycin and daunomycin. J. Natl. Cancer Inst. 1981, 66, 81-84.
32. Purewal, M.; Liehr, J. G. Covalent modification of DNA by daunorubicin. Cancer Chemother. Pharmacol. 1993, 33, 239-244.
33. Bartoszek, A.; Wolf, C. R. Enhancement of doxorubicin toxicity following activation by NADPH cytochromeP450 reductase. Biochem. Pharmacol. 1992, 43, 1449-1457.
34. Averbuch, S. D.; Gaudiano, G.; Koch, T. H.; Bachur, N. R. Radical dimer rescue of toxicity and improved therapeutic index of Adriamycin in tumor-bearing mice. Cancer Res. 1985, 45, 6200-6204.
35. Acton, E. M.; Tong, G. L.; Mosher, C. W.; Wolgemuth, R. L. Intensely Potent Morpholinyl Antnracyclines. J. Med. Chem. 1984, 27, 638-645.
36. Uchida, T.; Imoto, M.; Takahashi, Y.; Odagawa, A.; Sawa, T.; Tatsuta, K.; Naganawa, H.; Hamada, M.; Takeuchi, T.; Umezawa, H. New potent anthracyclines, barminomycins I and II. J. Antibiot. 1988, 41, 404-408.
37. Ikeda, D.; Ajito, K.; Kondo, S.; Takeuchi, T. Synthesis of 3″-dehydro-4-O-methylbarminomycin II having an eight-membered acetal-azomethine ring. Chem. Lett. 1990, 1431-1432.
38. Nagy, A.; Armatis, P.; Schally, A. V. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2464-2469.
39. Zwelling, L. A.; Altschuler, E.; Cherif, A.; Farquhar, D. N-(5,5-Diacetoxypentyl)doxorubicin: A novel anthracycline producing DNA interstrand cross-linking and rapid endonucleolytic cleavage in human leukemia cells. Cancer Res. 1991, 57, 6704-6707.
40. Cherif, A.; Farquhar, D. N-(5,5-Diacetoxypent-1-yl)doxorubicin: A New Intensely Potent Doxorubicin Analogue. J. Med. Chem. 1992, 35, 3208-3214.
41. Walker, J. F. Formaldehyde, 3rd ed.; Reinhold: New York, 1964; pp 244-245.